Drugs / 177Lu-DOTA-EB-TATE
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05475210 | Jun 2022 → Dec 2024 | neuroendocrine neoplasm | Molecular Targeting Technologies, Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT03478358 | Apr 2017 → Dec 2022 | neuroendocrine neoplasm | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT03308682 | Apr 2017 → May 2018 | neuroendocrine neoplasm | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06991738 | Oct 2026 → Jul 2032 expected | thyroid cancer | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177LuDOTA-EB-TATE | “An Evans blue-modified 177 Lu-labeled octreotate ( 177 Lu-DOTA-EB-TATE) has an extended circulation in the blood, which may make the amino acid infusion unnecessary.” PMID 37075254 ↗ Apr 20235“The patients were intravenously injected with single dose 0.37GBq-0.74GBq (10-30 mCi) of 177LuDOTA-EB-TATE” NCT03478358 ↗ |
| Modality | Peptide | “long-lasting radiolabeled somatostatin analogue based peptide receptor radionuclide therapy” NCT03308682 ↗ |
| Route | Intravenous | “will be injected intravenously” NCT03308682 ↗ |